Aiforia adds fourth CE-IVD marked clinical AI Model to its rapidly expanding portfolio of novel tools for cancer diagnostics
Aiforia Technologies Plc, Press Release, 25 May, 2022 at 12.00 p.m. EEST. Aiforia announces the CE-IVD marking of the Aiforia® Clinical AI Model for Breast Cancer; PR. The news comes just recently after the company released another CE-IVD marked clinical algorithm, the ER AI model, for the same disease. Aiforia is providing a uniquely comprehensive approach to breast cancer diagnostics as the majority of cases express ER and/or PR. Therefore, the two are considered to be the most significant biomarkers involved in the evaluation of breast cancer.“Since ER and PR positivity in breast cancer